{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+ketamine",
    "query": {
      "intervention": "Intranasal ketamine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intranasal+ketamine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T17:53:17.674Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04150757",
      "title": "Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-Occlusive Pain Episode in Sickle Cell Disease",
        "Vaso-occlusive Crisis",
        "Ketamine",
        "Intranasal Ketamine",
        "Analgesia"
      ],
      "interventions": [
        {
          "name": "Intranasal ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abigail Nixon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-12-19",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 2,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04150757"
    },
    {
      "nct_id": "NCT00520169",
      "title": "Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "intranasal ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Javelin Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-07",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2008-01-10",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520169"
    },
    {
      "nct_id": "NCT02497287",
      "title": "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Depression"
      ],
      "interventions": [
        {
          "name": "Esketamine (Intranasal Spray)",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 802,
      "start_date": "2015-09-30",
      "completion_date": "2017-10-28",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 16,
      "location_summary": "New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497287"
    },
    {
      "nct_id": "NCT03466242",
      "title": "IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Conscious Sedation",
        "Distal Radius Fracture"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phoenix Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-01-01",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03466242"
    },
    {
      "nct_id": "NCT06795659",
      "title": "Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder PTSD"
      ],
      "interventions": [
        {
          "name": "Esketamine (Intranasal Spray)",
          "type": "DRUG"
        },
        {
          "name": "Massed Prolonged Exposure (PE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2025-06-09",
      "completion_date": "2026-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06795659"
    },
    {
      "nct_id": "NCT03539887",
      "title": "Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Suicidal Ideation",
        "Depression",
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "Intranasal ketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 33,
      "start_date": "2018-05-01",
      "completion_date": "2022-01-15",
      "has_results": true,
      "last_update_posted_date": "2023-03-01",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03539887"
    },
    {
      "nct_id": "NCT03097133",
      "title": "54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 230,
      "start_date": "2017-06-15",
      "completion_date": "2019-04-11",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03097133"
    },
    {
      "nct_id": "NCT05934669",
      "title": "IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Laceration of Skin",
        "Anxiety",
        "Discharge Time"
      ],
      "interventions": [
        {
          "name": "Intranasal Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Intranasal Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Intranasal Ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "1 Year to 5 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-11-14",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05934669"
    },
    {
      "nct_id": "NCT00492388",
      "title": "Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "PMI-150 (intranasal ketamine)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospira, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2012-01-11",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492388"
    },
    {
      "nct_id": "NCT02417064",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment-resistant Depression"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram (Oral antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Sertraline (Oral Antidepressant)",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine Extended Release (XR) (Oral Antidepressant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 346,
      "start_date": "2015-08-10",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-09-06T17:53:17.674Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02417064"
    }
  ]
}